Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/S0091-679X(06)79015-X | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Anti-VEGF drugs compared with laser photocoagulation for the treatment of diabetic retinopathy: a systematic review and meta-analysis.
Health Technol Assess
December 2024
Biosciences Institute, Newcastle University, Newcastle upon Tyne, UK.
Background: Diabetic retinopathy is a major cause of sight loss in people with diabetes. The most severe form, proliferative diabetic retinopathy, carries a high risk of vision loss, vitreous haemorrhage, macular oedema and other harms. Panretinal photocoagulation is the primary treatment for proliferative diabetic retinopathy.
View Article and Find Full Text PDFFilgotinib in Active Noninfectious Uveitis: The HUMBOLDT Randomized Clinical Trial.
JAMA Ophthalmol
September 2024
Legacy Devers Eye Institute, Portland, Oregon.
Article Synopsis
- - Noninfectious uveitis is a major cause of vision loss and there is a need for better treatment options, prompting the investigation of filgotinib, a JAK1 inhibitor, for this condition.
- - The HUMBOLDT trial was a phase 2 study involving 74 participants, aged 18 and older, with active noninfectious uveitis, comparing filgotinib to a placebo over 52 weeks.
- - Results showed that 37.5% of those on filgotinib experienced treatment failure by week 24, significantly lower than the 67.6% for placebo, indicating that filgotinib may be an effective option for treating this illness.
Changes in activity impairment and work productivity after treatment for vitreous hemorrhage due to proliferative diabetic retinopathy: Secondary outcomes from a randomized controlled trial (DRCR Retina Network Protocol AB).
PLoS One
November 2023
Charlotte Eye, Ear, Nose, and Throat Associates, Charlotte, North Carolina.
Background: Vitreous hemorrhage from proliferative diabetic retinopathy can cause severe vision loss. DRCR Retina Network Protocol AB was a randomized clinical trial comparing intravitreal aflibercept versus vitrectomy with panretinal photocoagulation and found no difference in the average rate of visual recovery over 104 weeks. Herein, we describe patient-reported outcome measures from Protocol AB.
View Article and Find Full Text PDFOrbital Gas after 25-Gauge Pars Plana Vitrectomy with Incorrect Gas Mixture.
Case Rep Ophthalmol
July 2023
Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL, USA.
We present 2 cases of sutureless 25-gauge pars plana vitrectomy and fluid-gas exchange, in which incorrect gas concentrations likely led to elevated intraocular pressures and retrobulbar gas. Combined removal of orbital gas with anterior orbitotomy and pars plana vitrectomy was performed in the first case to address expanding intraocular and retrobulbar gas resulting from a suspected error in gas dilution. Vitreous and orbital gas removal by needling was effective in the second case.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!